litlas
ログインアカウント作成

Leisha A. Emens

1992–2025 年に発表

94
論文数
20,093
被引用数
62
h 指数
93
i10 指数

被引用数

Leisha A. Emens の年別被引用数1993 年: 被引用 3 件1994 年: 被引用 6 件1996 年: 被引用 4 件1997 年: 被引用 4 件1998 年: 被引用 5 件1999 年: 被引用 6 件2000 年: 被引用 4 件2001 年: 被引用 11 件2002 年: 被引用 15 件2003 年: 被引用 14 件2004 年: 被引用 19 件2005 年: 被引用 24 件2006 年: 被引用 56 件2007 年: 被引用 46 件2008 年: 被引用 58 件2009 年: 被引用 37 件2010 年: 被引用 78 件2011 年: 被引用 54 件2012 年: 被引用 73 件2013 年: 被引用 79 件2014 年: 被引用 48 件2015 年: 被引用 98 件2016 年: 被引用 131 件2017 年: 被引用 193 件2018 年: 被引用 182 件2019 年: 被引用 834 件2020 年: 被引用 1,421 件2021 年: 被引用 1,678 件2022 年: 被引用 1,377 件2023 年: 被引用 996 件2024 年: 被引用 1,237 件2025 年: 被引用 612 件2026 年: 被引用 18 件1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,724 件、この内訳の 24.6%中国: 引用元論文 1,993 件、この内訳の 18%イタリア: 引用元論文 608 件、この内訳の 5.5%イギリス: 引用元論文 460 件、この内訳の 4.1%フランス: 引用元論文 435 件、この内訳の 3.9%ドイツ: 引用元論文 407 件、この内訳の 3.7%スペイン: 引用元論文 329 件、この内訳の 3%オーストラリア: 引用元論文 306 件、この内訳の 2.8%日本: 引用元論文 290 件、この内訳の 2.6%カナダ: 引用元論文 289 件、この内訳の 2.6%ベルギー: 引用元論文 242 件、この内訳の 2.2%韓国: 引用元論文 231 件、この内訳の 2.1%
0%24.6%その他 24.9%

機関

分野

  • Medicine57.5%
  • Biochemistry, Genetics and Molecular Biology20.5%
  • Immunology and Microbiology14.9%
  • Engineering3.1%
  • Neuroscience1.3%
  • Materials Science1%
  • その他1.7%

トピック

  • Cancer Immunotherapy and Biomarkers15.4%
  • Immunotherapy and Immune Responses8%
  • CAR-T cell therapy research4%
  • Immune Cell Function and Interaction3.9%
  • Immune cells in cancer3.7%
  • Cancer Cells and Metastasis2.8%
  • その他62.2%

共著者

全論文

検索で開く
  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    著者: Peter Schmid, Sylvia Adams, Hope S. Rugo, Andreas Schneeweiss, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Roberto Hegg, Seock‐Ah Im, Gail S. Wright, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Roel Funke, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens - New England Journal of Medicine 2018 被引用: 4,369

  2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Peter Schmid, Hope S. Rugo, Sylvia Adams, Andreas Schneeweiß, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Vidya Maiya, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens - The Lancet Oncology 2019 被引用: 1,198

  3. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

    著者: Suzanne L. Topalian, Patrick M. Forde, Leisha A. Emens, Mark Yarchoan, Kellie N. Smith, Drew M. Pardoll - Cancer Cell 2023 被引用: 277

  4. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

    著者: Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Véronique Dièras, Hiroji Iwata, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Eric P. Winer, Shilpen Patel, Volkmar Henschel, A. Swat, Manika Kaul, Luciana Molinero, Shilpen Patel, S.Y. Chui, P. Schmid - Annals of Oncology 2021 被引用: 468

  5. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

    著者: Leisha A. Emens, Cristina Cruz, Joseph P. Eder, Fadi Braiteh, Cathie T. Chung, Sara M. Tolaney, Irene Kuter, Rita Nanda, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Ehab A. ElGabry, Ching-Wei Chang, Indrani Sarkar, William Grossman, Carol O’Hear, Marcella Fassò, Luciana Molinero, Peter Schmid - JAMA Oncology 2018 被引用: 793

  6. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

    著者: Leisha A. Emens, Francisco J. Esteva, Mark Beresford, Cristina Saura, Michelino De Laurentiis, Sung‐Bae Kim, Seock‐Ah Im, Yifan Wang, Roberto Salgado, Aruna Mani, Jigna Shah, Chiara Lambertini, Haiying Liu, Sanne Lysbet de Haas, Monika Patre, Sherene Loi - The Lancet Oncology 2020 被引用: 375

  7. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy

    著者: Mahrukh Huseni, Lifen Wang, Joanna E. Klementowicz, Kobe Yuen, Beatrice Breart, Christine Orr, Lifen Liu, Yijin Li, Vinita Gupta, Congfen Li, Deepali Rishipathak, Jing Peng, Yasin Şenbabaoğlu, Zora Modrušan, Shilpa Keerthivasan, Shravan Madireddi, Ying‐Jiun Chen, Eleanor J. Fraser, Ning Leng, Habib Hamidi, Hartmut Koeppen, James Ziai, Kenji Hashimoto, Marcella Fassò, Patrick Williams, David F. McDermott, Jonathan E. Rosenberg, Thomas Powles, Leisha A. Emens, Priti S. Hegde, Ira Mellman, Shannon J. Turley, Mark S. Wilson, Sanjeev Mariathasan, Luciana Molinero, Mark Merchant, Nathaniel R. West - Cell Reports Medicine 2023 被引用: 183

  8. Breast Cancer Immunotherapy: Facts and Hopes

    著者: Leisha A. Emens - Clinical Cancer Research 2017 被引用: 929

  9. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

    著者: Luc Dirix, István Takács, Guy Jérusalem, Petros Nikolinakos, Hendrik‐Tobias Arkenau, Andres Forero‐Torres, Ralph V. Boccia, Marc E. Lippman, Robert A. Somer, Martin Šmakal, Leisha A. Emens, Borys Hrinczenko, W. Jeff Edenfield, Jayne S. Gurtler, Anja von Heydebreck, H. Grote, Kevin M. Chin, Erika Hamilton - Breast Cancer Research and Treatment 2017 被引用: 756

  10. The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

    著者: Leisha A. Emens, Gary Middleton - Cancer Immunology Research 2015 被引用: 821

  11. Targeting adenosine for cancer immunotherapy

    著者: Robert D. Leone, Leisha A. Emens - Journal for ImmunoTherapy of Cancer 2018 被引用: 543

  12. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

    著者: Leisha A. Emens, Luciana Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Véronique Dièras, Hiroji Iwata, Carlos H. Barrios, M. Nechaeva, Anh Nguyen‐Duc, Jane Yuet Ching Hui, Amreen Husain, Eric P. Winer, Sylvia Adams, Peter Schmid - JNCI Journal of the National Cancer Institute 2021 被引用: 306

  13. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

    著者: Leisha A. Emens, Pedro Romero, Ana C. Anderson, Tullia C. Bruno, Christian M. Capitini, Deborah Collyar, James L. Gulley, Patrick Hwu, Avery D. Posey, Ann W. Silk, Jennifer A. Wargo - Journal for ImmunoTherapy of Cancer 2024 被引用: 146

  14. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

    著者: Leisha A. Emens, Paolo A. Ascierto, Phillip K. Darcy, Sandra Demaria, Alexander M.M. Eggermont, William L. Redmond, Barbara Seliger, Francesco M. Marincola - European Journal of Cancer 2017 被引用: 562

  15. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

    著者: Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol, Rebecca S. Heist, Toni K. Choueiri, Saby George, Brett Hughes, Matthew D. Hellmann, Dale R. Shepard, Brian I. Rini, Shivaani Kummar, Amy Weise, Matthew J. Riese, Ben Markman, Leisha A. Emens, Daruka Mahadevan, Jason J. Luke, Ginna G. Laport, Joshua Brody, Leonel F. Hernandez‐Aya, Philip Bonomi, Jonathan W. Goldman, Lyudmyla Berim, Daniel J. Renouf, Rachel Goodwin, Brian Munneke, Po Y. Ho, Jessica Hsieh, Ian McCaffery, Long Kwei, Stephen B. Willingham, Richard A. Miller - Cancer Discovery 2019 被引用: 339

  16. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

    著者: Kyung Hae Jung, Patricia LoRusso, Howard A. Burris, Michael A. Gordon, Yung‐Jue Bang, Matthew D. Hellmann, Andrés Cervantes, María Ochoa de Olza, Aurélien Marabelle, F. Stephen Hodi, Myung‐Ju Ahn, Leisha A. Emens, Fabrice Barlési, Omid Hamid, Emiliano Calvo, David F. McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Lew Tsuhako, Kari M. Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis - Clinical Cancer Research 2019 被引用: 286

  17. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

    著者: Ashley Cimino‐Mathews, Elizabeth D. Thompson, Janis M. Taube, Xiaobu Ye, Lu Yao, Alan K. Meeker, Haiying Xu, Rajni Sharma, Kristen Lecksell, Toby C. Cornish, Nathan Cuka, Pedram Argani, Leisha A. Emens - Human Pathology 2015 被引用: 338

  18. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer

    著者: Hope S. Rugo, Sherene Loi, Sylvia Adams, Peter Schmid, Andreas Schneeweiß, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Eric P. Winer, Mark Kockx, Dieter Peeters, Jane Yuet Ching Hui, Jennifer Lin, Anh Nguyen-Duc, Giuseppe Viale, Luciana Molinero, Leisha A. Emens - JNCI Journal of the National Cancer Institute 2021 被引用: 140

  19. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

    著者: Jeremy B. Foote, Marleen Kok, James M. Leatherman, Todd D. Armstrong, Bridget C. Marcinkowski, Laureen S. Ojalvo, David B. Kanne, Elizabeth M. Jaffee, Thomas W. Dubensky, Leisha A. Emens - Cancer Immunology Research 2017 被引用: 149

  20. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

    著者: Li Zhu, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, Rim Kim, Katherine L. Pogue–Geile, Sarah Sammons, Naema Nayyar, Ugonma Chukwueke, Priscilla K. Brastianos, Carey K. Anders, Adam C. Soloff, Dario A.A. Vignali, George C. Tseng, Leisha A. Emens, Peter C. Lucas, Kimberly Blackwell, Steffi Oesterreich, Adrian V. Lee - Journal for ImmunoTherapy of Cancer 2019 被引用: 124

  21. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

    著者: Leisha A. Emens, Sylvia Adams, Ashley Cimino‐Mathews, Mary L. Disis, Margaret E. Gatti‐Mays, Alice Y. Ho, Kevin Kalinsky, Heather L. McArthur, Elizabeth A. Mittendorf, Rita Nanda, David B. Page, Hope S. Rugo, Krista M. Rubin, Hatem Soliman, Patricia A. Spears, Sara M. Tolaney, Jennifer K. Litton - Journal for ImmunoTherapy of Cancer 2021 被引用: 81

  22. Immunotherapy Approaches for Breast Cancer Patients in 2023

    著者: Leisha A. Emens, Sherene Loi - Cold Spring Harbor Perspectives in Medicine 2023 被引用: 64

  23. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies

    著者: Evanthia T. Roussos Torres, Leisha A. Emens - Breast Cancer Research and Treatment 2021 被引用: 44

  24. Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer

    著者: Hanwen Wang, Chen Zhao, Cesar A. Santa‐Maria, Leisha A. Emens, Aleksander S. Popel - iScience 2022 被引用: 39